Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Gut. 2013 May 3;63(4):656–664. doi: 10.1136/gutjnl-2012-304287

Figure 1.

Figure 1

Nr5a2 is downregulated in acini expressing oncogenic Kras that undergo acinar to ductal metaplasia (ADM)/pancreatic intraepithelial neoplasia (PanIN) lesion formation and in pancreatic ductal adenocarcinoma (PDA). (A) Nr5a2 staining on pancreata at different time points (day 2 and 7) after pancreatitis induction or PBS injection of Ptf1aCre; KrasG12D mice; arrows mark Nr5a2 positive cells, arrowheads mark Nr5a2 negative cells. Upper panel: Immunohistochemistry staining for Nr5a2. Lower panel: Immunofluorescent co-staining of acinar tissue or ADM/PanIN lesions for CPA1, Clusterin and Nr5a2. Clusterin positive persistent ADM and early PanIN lesions exhibit strong reduction of nuclear Nr5a2. Note that the specific Nr5a2 staining is nuclear, whereas cytoplasmic staining is unspecific background. (B) Nr5a2 staining on pancreata 7 days after caerulein induction or PBS injection of ElastaseCreERT2; KrasG12D; R26REYFP mice. Depicted is an YFP positive PanIN lesion lacking nuclear Nr5a2, which occurred 7 days after caerulein induction; arrows mark Nr5a2 positive cells, arrowheads mark Nr5a2 negative cells. (C) RNA expression of Nr5a2 during indicated time points after pancreatitis induction in Ptf1aCre; KrasG12D mice. p Values are relative to PBS treated animals; values are shown as mean±SEM. (D) Nr5a2 staining of a PDA derived from a Ptf1aCre; KrasG12D mouse. (A) Upper panel: scale bar 50 μm. Lower panel: scale bar 10 μm. (B) Scale bar 10 μm. (D) Scale Bar 500 μm.